Welcome to Epivantage
Mission: create the best epidemiological datasets and insights
Epivantage was founded in 2021 by Dr Mike Hughes as a response to the frequent lack of rigorous methods and fine-grained populations in epidemiological forecasts, particularly in the incorporation of real-world evidence and genetically-defined tumour populations.
Epivantage works with leading epidemiologists in different therapeutic areas and regularly surveils the evidence landscape to support their forecast models and insights. The resulting on-demand reports fulfil the needs of modern pharma companies for reliable and up-to-date insights to support their strategic planning and marketing.
This month’s report in focus:
Key results:
– We estimate 140,846 advanced 1st line drug-treatable cases nationally in 2022. Of these, we estimate 93,883 (67%) are drug-treated at 1st line, and 46,575 (33%) drug-treated at 2nd line
– Nationally, the number of incident cases over our 20-year forecast period will increase by 19%.
– We estimate 140,846 advanced 1st line drug-treatable cases nationally in 2022, 159,811 in 2032 and 166,302 in 2042.
Click here to download the executive summary
Our range of services
Our off-the-shelf Cancer Populations USA and on-demand Global Cancer Epidemiology Forecast report series provide our clients with industry-leading and robustly researched information.
Our custom reports are likewise the result of in-depth primary and secondary research, and our consulting service provides clients with expertise in the design and execution of real-world evidence and epidemiological studies.
To request a free sample report, please complete this form. For all other inquiries, please email us at questions@epivantage.com, or use our inquiry form.
Epivantage leadership
Epivantage was founded in 2021 by Dr Mike Hughes who, over many years supporting pharma companies, created many of the advanced techniques for epidemiological forecasting. Epivantage applies these gold-standard methods to fine-grained epidemiological forecasts with the incorporation of real-world evidence and genetically-defined tumour populations.
Epivantage has a network of epidemiologists that regularly survey the evidence landscape to support their forecast models and insights. The resulting reports created by Epivantage fulfil the needs of modern pharma companies for reliable and up-to-date insights to support their strategic planning and market access plans.
Contact us with any questions.
